select a format

Single User License
USD 2000 INR 130240
Site License
USD 4000 INR 260480
Corporate User License
USD 6000 INR 390720

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Pipeline Review, H2 2016

Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Pipeline Review, H2 2016


  • Products Id :- GMDHC8892IDB
  • |
  • Pages: 31
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Bowel Dysfunction-Pipeline Review, H2 2016, provides an overview of the Opioid-Induced Bowel Dysfunction (Toxicology) pipeline landscape.

Opioid-induced bowel dysfunction (OIBD) is refers to a collection of primarily gastrointestinal motility disorders induced by opioids. OIBD is commonly associated with the chronic use of opioid analgesics. Symptoms include constipation, anorexia, nausea and vomiting, gastro-oesophageal reflux, delayed digestion, abdominal pain, flatulence, bloating, hard stool, straining during bowel movement and incomplete evacuation. Treatment includes laxatives, stool softeners, osmotic agents and opioid antagonist.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Bowel Dysfunction-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Opioid-Induced Bowel Dysfunction (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opioid-Induced Bowel Dysfunction (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 3 respectively.

Opioid-Induced Bowel Dysfunction (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Bowel Dysfunction (Toxicology).

The pipeline guide reviews pipeline therapeutics for Opioid-Induced Bowel Dysfunction (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Opioid-Induced Bowel Dysfunction (Toxicology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Opioid-Induced Bowel Dysfunction (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Bowel Dysfunction (Toxicology)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Bowel Dysfunction (Toxicology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Opioid-Induced Bowel Dysfunction (Toxicology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Opioid-Induced Bowel Dysfunction (OBD or OIBD) Overview 6

Therapeutics Development 7

Pipeline Products for Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Overview 7

Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Therapeutics under Development by Companies 8

Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Pipeline Products Glance 9

Early Stage Products 9

Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Products under Development by Companies 10

Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Companies Involved in Therapeutics Development 11

ChironWells GmbH 11

Orphomed Inc 12

RaQualia Pharma Inc 13

Vitality Biopharma Inc 14

Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Therapeutics Assessment 15

Assessment by Monotherapy Products 15

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Drug Profiles 23

ORP-102-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

ORP-106-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

RQ-00433412-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Small Molecule to Antagonize Mu Opioid Receptor for Gastrointestinal Disorders-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

VB-100-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

VB-210-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Dormant Projects 29

Appendix 30

Methodology 30

Coverage 30

Secondary Research 30

Primary Research 30

Expert Panel Validation 30

Contact Us 30

Disclaimer 31

List of Figures

Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 9

Assessment by Monotherapy Products, H2 2016 15

Number of Products by Targets, H2 2016 16

Number of Products by Stage and Targets, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Stage and Molecule Types, H2 2016 22

List of Tables

Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Early Stage Development, H2 2016 9

Products under Development by Companies, H2 2016 10

Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Pipeline by ChironWells GmbH, H2 2016 11

Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Pipeline by Orphomed Inc, H2 2016 12

Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Pipeline by RaQualia Pharma Inc, H2 2016 13

Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Pipeline by Vitality Biopharma Inc, H2 2016 14

Assessment by Monotherapy Products, H2 2016 15

Number of Products by Stage and Target, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 22

Opioid-Induced Bowel Dysfunction (OBD or OIBD)-Dormant Projects, H2 2016 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ChironWells GmbH, Orphomed Inc, RaQualia Pharma Inc, Vitality Biopharma Inc

Opioid-Induced Bowel Dysfunction (OBD or OIBD) Therapeutic Products under Development, Key Players in Opioid-Induced Bowel Dysfunction (OBD or OIBD) Therapeutics, Opioid-Induced Bowel Dysfunction (OBD or OIBD) Pipeline Overview, Opioid-Induced Bowel Dysfunction (OBD or OIBD) Pipeline, Opioid-Induced Bowel Dysfunction (OBD or OIBD) Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com